| Catalog No. |
TD-HF543016 |
| Description |
ANB020, now called etokimab, is currently in phase 2a testing in eczema, which is also known as atopic dermatitis. Scientists from the Medical Research Council Human Immunology Unit at the University of Oxford released data from 12 patients showing that 83% who were treated with etokimab reported a reduction in disease severity after 29 days. Etokimab, an anti-IL-33 biologic, has previously demonstrated a good safety profile and favorable pharmacodynamic properties in many clinical studies. Etokimab is designed to block interleukin-33 (IL-33), an immune-signaling molecule. In peanut allergy, the body overreacts to peanuts as IL-33 activates an antibody called immunoglobin E. These antibodies cause allergic response such as mouth itchiness, hives, breathing difficulties and potentially fatal anaphylactic shock. |
| Species reactivity |
Human |
| Applications |
Research Grade Biosimilar |
| Host species |
Humanized |
| Isotype |
IgG1-kappa |
| Expression system |
Mammalian Cells |
| Species |
Human |
| Clonality |
Monoclonal |
| Target |
NF-HEV, IL-1F11, C9orf26, IL-33, Interleukin-1 family member 11, IL33, Nuclear factor from high endothelial venules, NFHEV, Interleukin-33, IL1F11 |
| Endotoxin level |
Please contact with the lab for this information. |
| Purity |
>95% as determined by SDS-PAGE. |
| Purification |
Protein A/G purified from cell culture supernatant. |
| Accession |
O95760 |
| Form |
Liquid |
| Storage buffer |
0.01M PBS, pH 7.4. |
| Stability and Storage |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term. |
| Alternate Names |
ANB020, CAS: 2022981-44-6,IL33 |
| Background |
Etokimab (Antibody ANB 020) is a humanized monoclonal antibody that targets IL-33. Etokimab can be used for the research of atopic dermatitis. |
| Note |
For research use only. Not suitable for clinical or therapeutic use. |
抗体
试剂盒
多肽
探针
蛋白
组织芯片
定制服务咨询